ArticleCancer medicine2024
Cerebrospinal Fluid Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study in China.
Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The evolving landscape of CAR T cell therapy in children and young adults with B cell acute lymphoblastic leukemia.Molecular therapy. Oncology · 2026Review
- CD79A and IL7R mRNA Levels in the Cerebrospinal Fluid of Adults with Acute B-Cell Lymphoblastic Leukemia: A Pilot Study.Diseases (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveThe central nervous system (CNS) is a frequent site of relapse in childhood acute lymphoblastic leukemia (ALL). This study aims to investigate the utility of cerebrospinal fluid (CSF) flow cytometry in detecting CNS infiltration and relapse.
methodsFlow cytometry was used to detect CSF leukemia cells, and patients were categorized into the CSF Flow+ and CSF Flow- groups. The primary outcome was the cumulative incidence of relapse (CIR) in the CSF Flow+ and CSF Flow- groups.
resultsA total of 1301 patients were enrolled, 159 patients (12.2%) showed positive CSF flow cytometry results. The CNS Flow+ patients exhibited significantly higher rates of any CNS relapse (22.5% vs. 0.2%, p < 0.01) and isolated CNS relapse (10.7% vs. 0%, p < 0.01) compared to CNS Flow- patients. Cox regression analysis revealed that risk factors for isolated CNS relapse included a positive result of D46 minimal residual disease (MRD) and CSF Flow+ at a non-initial diagnosis. For any CNS relapse, the significant risk factors were CSF Flow+ at the initial diagnosis and CSF Flow+ at a non-initial diagnosis.
conclusionsCSF flow cytometry may have clinical utility in detecting CNS infiltration among pediatric ALL patients. It could contribute to more effective risk stratification and treatment adjustments and potentially reduce the risk of CNS relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.